Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancer

Phase 2

• Conditions: Resistant ovarian cancer

• Registration Number: JPRN-UMIN000007318
• Lead Sponsor: Kyorin University, School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with severe infectious disease and/or serious complication. 2) Patients who have severe gastrointestinal injury and/or gastrointestinal bleeding. 3) Patients who have necessary ascites and/or pleural effusion of measures. 4) Patients with interstitial pneumonia. 5) Patients with ileus. 6) Patients with active brain metastases. 7) Patients with active double cancer. 8) Patients who carried out bone marrow transplantation. 9) Patients who have the past of serious hypersensitivity. 10) Patients who are pregnant or who are at risk of pregnancy, or those who desire to become pregnant during their participation. 11) Patients who have uncontrolled diabetes mellitus. 12) Patients who received topoisomerase I inhibitor and/or topoisomerase II inhibitor containing chemotherapy within 6 months. 13) Inappropriate patients for this study judged by the physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate, Safty

Secondary Outcome Measures

Name	Time	Method
Disease control rate,Progression-free survival, Overall survival,